{{Rsnum
|rsid=1059231
|Gene=DAXX
|Chromosome=6
|position=33320494
|Orientation=minus
|GMAF=0.2401
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=DAXX
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 9.7 | 38.1 | 52.2
| HCB | 4.5 | 35.3 | 60.2
| JPT | 5.3 | 35.4 | 59.3
| YRI | 0.0 | 1.4 | 98.6
| ASW | 0.0 | 17.9 | 82.1
| CHB | 4.5 | 35.3 | 60.2
| CHD | 4.6 | 36.7 | 58.7
| GIH | 9.0 | 48.0 | 43.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 16.1 | 53.6 | 30.4
| MKK | 0.0 | 1.3 | 98.7
| TSI | 8.9 | 42.6 | 48.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1059231
|Name_s=exon 4 Y379Y, c.1137T>C, mRNA 1252T>C, Tyr379Tyr
|Gene_s=DAXX, ZBTB22, TAPBP
|Feature=
|Evidence=PubMed ID:19837266
|Annotation=Risk or phenotype-associated allele, tested allele: unspecified; multiethnic minor allele is C per dbSNP Phenotype: In 114 cases and 414 controls (n = 528), univariate analysis of disease association showed OR = 0.87 for heterozygote, OR = 1.38 for homozygous, versus homozygous wild type, in ALL, with P(trend) OR = 1.08, p = 0.61 using an additive model. Study size: 528. Study population/ethnicity: Childhood acute lymphoblastic leukemia (<=14 years) and healthy newborn controls (1988 to 1999) from South Wales in the United Kingdom. Significance metric(s): Non-significant finding p = 0.61. Type of association: CO.
|Drugs=
|Drug Classes=
|Diseases=Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA165110225
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1059231
|overall_frequency_n=2353
|overall_frequency_d=10758
|overall_frequency=0.218721
|n_genomes=20
|n_genomes_annotated=0
|n_haplomes=24
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}